Pneumagen ^Companies

Pneumagen is a clinical-stage biotech company that focuses on developing glycan targeted carbohydrate-binding modules (CBMs) for the prevention and treatment of respiratory tract infections (RTIs) and cancer. Their lead product, Neumifil, is an intranasal drug designed to prophylaxis and treat a broad range of viral RTIs. Pneumagen's mission is to develop innovative, life-saving antiviral therapies for at-risk patients vulnerable to respiratory tract infections. Neumifil is a novel, engineered multivalent Carbohydrate Binding Module (mCBM) that targets various viral respiratory infections, including Influenza Virus, Respiratory Syncytial Virus, Human Rhinovirus, and Coronavirus Infections.